Sanofi Pasteur Enters Agreement with Crucell for Next
... there is no treatment for rabies once symptoms of the disease have appeared. Post exposure
prophylaxis for severe bites requires both active immunization, using vaccines such as those
currently marketed by sanofi pasteur, and passive immunization in the form of rabies
immunoglobulins (RIG). Rabies m ...
World`s Leading Manufacturer, Seasonal Flu
... Pennsylvania, facility in the United States.
In June 2013, the U.S. FDA approved the supplemental biologics license application (sBLA) for
licensure of the new Sanofi Pasteur quadrivalent influenza vaccine (including four strains: two A
strains and two B strains), Fluzone® Quadrivalent, for pediat ...
Modèles Industriels 2011 Æterna Zentaris est une entreprise de
... Alkermes founders were initially drawn together by their interest in using novel technology to
address important, unmet medical needs. Today, the mission remains the same: we leverage
sophisticated extended-release drug technologies to create therapies for widespread diseases such
as central nervous ...
REGENERON PHARMACEUTICALS INC (Form: 8
... Vietnam, Myanmar, and Sri Lanka. The excluded territory comprises the territory for a previously announced fasinumab collaboration
between Regeneron and Mitsubishi Tanabe Pharma Corporation, which was entered into in September 2015.
Under the Collaboration Agreement, Regeneron is eligible to receive ...
Sanofi-Aventis Acquires Genzyme Corporation for $20 billion Brochure
... - On April 8, 2011, Sanofi-aventis completed the acquisition of Genzyme for about $20 billion in total, or $74
per share plus extra payments of up to $14 per share. The extra payments would depend on the
achievement of commercial milestones of the leukemia drug Campath (alemtuzumab) in the multiple
united states securities and exchange commission - corporate
... commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Ionis, Novartis, Roche,
Takeda, Merck, Monsanto, The Medicines Company, and Sanofi Genzyme. In addition, Alnylam holds an equity position in Regulus
Therapeutics Inc., a company focused on discove ...
Notice of meeting
... validly taken into account, confirmations have to be
received by BNP Paribas Securities Services on the eve of
the meeting at the latest, i.e. on May 9, 2017 at 3 p.m.
Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the world's fifth-largest by prescription sales. The company was formed as Sanofi-Aventis in 2004 by the merger of Aventis and Sanofi-Synthélabo, which were each the product of several previous mergers. It changed its name to Sanofi in May 2011.Sanofi engages in the research and development, manufacturing and marketing of pharmaceutical drugs principally in the prescription market, but the firm also develops over-the-counter medication. The company covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur).